Philipp Stroebel Selected Research

Philipp Stroebel Research Topics

Disease

9	Neoplasms (Cancer) 01/2017 - 09/2007
6	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2008
4	Thymoma (Thymic Carcinoma) 02/2019 - 07/2002
3	Prostatic Neoplasms (Prostate Cancer) 08/2013 - 09/2007
2	Disease Progression 12/2022 - 01/2013
2	Rectal Neoplasms (Rectal Cancer) 01/2022 - 07/2009
2	Myasthenia Gravis 02/2019 - 07/2002
2	Sarcoma (Soft Tissue Sarcoma) 04/2010 - 11/2008
1	Pancreatic Neoplasms (Pancreatic Cancer) 05/2024
1	Adenocarcinoma 05/2024
1	Inflammation (Inflammations) 12/2022
1	Fibrosis (Cirrhosis) 12/2022
1	Non-alcoholic Fatty Liver Disease 12/2022
1	Carcinoma (Carcinomatosis) 01/2022
1	Residual Neoplasm 01/2022
1	Microsatellite Instability 01/2022
1	Herpes Genitalis (Genital Herpes) 02/2019
1	Lichen Planus (Lichen Ruber Planus) 02/2019
1	Chronic Hepatitis (Chronic Active Hepatitis) 02/2019
1	Infections 02/2019
1	Exfoliative Dermatitis (Erythroderma) 02/2019
1	Cytomegalovirus Infections (Inclusion Disease) 02/2019
1	Candidiasis (Moniliasis) 02/2019
1	Respiratory Tract Infections (Respiratory Tract Infection) 02/2019
1	Alopecia (Baldness) 02/2019
1	Dermatomyositis (Dermatopolymyositis) 12/2015
1	Breast Neoplasms (Breast Cancer) 01/2009

Drug/Important Bio-Agent (IBA)

4	Biomarkers (Surrogate Marker)IBA 01/2017 - 07/2009
3	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 05/2010 - 01/2008
3	Proteins (Proteins, Gene)FDA Link 05/2010 - 01/2008
2	EnzymesIBA 05/2024 - 12/2022
2	Urokinase Plasminogen Activator ReceptorsIBA 05/2010 - 01/2009
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 04/2010 - 09/2009
1	Antineoplastic Agents (Antineoplastics)IBA 05/2024
1	Gemcitabine FDA Link 05/2024
1	ursodoxicoltaurineIBA 12/2022
1	InflammasomesIBA 12/2022
1	Transcription Factors (Transcription Factor)IBA 12/2022
1	Trastuzumab (Herceptin)FDA Link 01/2022
1	Epidermal Growth Factor (EGF)IBA 01/2022
1	AutoantibodiesIBA 02/2019
1	Chromogranin AIBA 01/2017
1	SteroidsIBA 12/2015
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2013
1	Fibronectins (Fibronectin)IBA 08/2013
1	MicroRNAs (MicroRNA)IBA 01/2013
1	Peptides (Polypeptides)IBA 05/2010
1	PlasminogenIBA 05/2010
1	AntibodiesIBA 05/2010
1	Plasminogen InactivatorsIBA 05/2010
1	Serine Proteases (Serine Protease)IBA 05/2010
1	Ifosfamide FDA LinkGeneric 04/2010
1	Etoposide (VP 16)FDA LinkGeneric 04/2010
1	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2010
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2010
1	somatostatin receptor 2IBA 09/2009
1	SirtuinsIBA 09/2009
1	Gallium-68IBA 09/2009
1	DOTA-Tyr(3)- 90Y-octreotideIBA 09/2009
1	Capecitabine (Xeloda)FDA Link 07/2009
1	Irinotecan (Camptosar)FDA LinkGeneric 07/2009
1	Type I DNA Topoisomerases (Topoisomerase I)IBA 07/2009
1	Biological FactorsIBA 01/2009
1	AntigensIBA 01/2009
1	Tissue ExtractsIBA 01/2009
1	ParaffinIBA 01/2009
1	Plasminogen Activator Inhibitor 1IBA 01/2009
1	Formaldehyde (Formol)FDA Link 01/2009
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2008
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 09/2007
1	Insulin-Like PeptidesIBA 09/2007
1	Insulin (Novolin)FDA Link 09/2007
1	C 27 (C-27)IBA 07/2002

Therapy/Procedure

6	Therapeutics 01/2022 - 07/2002
3	Neoadjuvant Therapy 01/2022 - 07/2009
2	Aftercare (After-Treatment) 01/2022 - 09/2009
2	Drug Therapy (Chemotherapy) 12/2015 - 07/2002
2	Radiotherapy 09/2009 - 11/2008
1	Gastrectomy 01/2022
1	Lymph Node Excision (Lymph Node Dissection) 01/2022
1	Chemoradiotherapy 01/2022
1	Thymectomy 02/2019
1	Microspheres (Microsphere) 09/2009
1	Lasers (Laser) 01/2009
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 11/2008
1	Adjuvant Chemoradiotherapy 07/2002